CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Ropivacaine +2 moredrug
Likely dose
Ropivacaine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05667324
NCT05667324Phase 4Completed

Post-operative Pain Control With Sphenopalantine Ganglion Nerve Block in Septorhinoplasty Patients

University of Florida·interventional·Posted Dec 28, 2022·Updated Apr 27, 2026

In Brief

A Phase 4 clinical trial evaluating Ropivacaine, Dexamethasone, and 1 other intervention for Deviated Nasal Septum. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Maxillary nerve blocks have been shown to significantly reduce post-operative pain and analgesic intake during the 24-hour period following sinus surgery. This randomized, double-blinded, placebo-controlled study will investigate blocks of the sphenopalatine ganglion using a suprazygomatic approach during septorhinoplasty surgery. It is the investigator's hypothesis that this technique will result in decreased post-operative pain and opioid use, and the morbidity associated with it.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedDec 28, 2022
Enrollment StartApr 12, 2023
Primary CompletionFeb 28, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.5 years ago

Interventions

Ropivacainedrug

A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)

Dexamethasonedrug

Plus 4 mg dexamethasone

Placebodrug

A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)